Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Medicare IVIG Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Immunoglobulin Therapy

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Medicare Part B coverage for intravenous and subcutaneous immune globulin therapy, including specified billing codes, coverage criteria, authorization periods, vendor requirements, and continuation documentation. It primarily applies to Medicare members receiving therapy for primary immunodeficiency.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Immunoglobulin Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain IVIG or SCIG from a preferred contracted IVIG vendor and secure prior authorization when billed under the medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    16

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Immune globulin products requiring prior authorization
    7Common procedure codes listed
    3 monthsInitial coverage period
    6 monthsExtension-of-therapy period
    Primary immunodeficiencyIVIG coverage indication

    Coverage Criteria

    IVIG for Primary Immunodeficiency

    Covered under Medicare Part B when applicable Medicare coverage guidance is met.

    IVIG coverage: IVIG is covered under the Part B benefit in all treatment settings for primary immunodeficiency.

    Refer to LCD L33610 and Policy Article A52509 for current coverage guidance.

    Home SCIG

    Covered under Medicare Part B when applicable Medicare coverage guidance is met.

    Home SCIG coverage: Subcutaneous immune globulin administered in the home setting follows Medicare guidance for external infusion pumps.

    Refer to LCD L33794 and Policy Article A52507 for current coverage guidance.

    Initial and Continuation Authorization

    Authorization periods are time limited.

    Initial authorization: Initial coverage may be authorized for up to 3 months.up to 3 months
    Continuation authorization: An extension requires pertinent laboratory reports and objective evidence of improvement and may be authorized for up to 6 months.up to 6 months

    Coverage is excluded when the requested therapy involves age, dose, dosing frequency, or duration outside FDA-approved package labeling.

    This policy does not address immunoglobulin preparations used for pre- or post-exposure prophylaxis for specific infectious diseases, including tetanus, rabies, hepatitis B, or cytomegalovirus.

    Billing and Procedure Codes

    Drugs Requiring Prior Authorization under the medical benefitHCPCS
    J1459Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g. liquid), 500 mg
    J1552Injection, immune globulin (Alyglo), 500 mg
    J1554Injection, immune globulin (Asceniv), 500 mg
    J1556Injection, immune globulin (Bivigam), 500 mg
    J1555Injection, immune globulin (Cuvitru)
    J1557Injection, immune globulin (Gammaplex), intravenous, non-lyophilized (e.g. liquid), 500 mg
    J1561Injection, immune globulin (Gamunex-C, Gammaked), intravenous, non-lyophilized (e.g. liquid), 500 mg
    J1566Injection, immune globulin, intravenous, lyophilized (e.g. powder), not otherwise specified, 500 mg; only Carimune NF and Gammagard S/D should be billed using this code
    J1568Injection, immune globulin (Octagam), intravenous, non-lyophilized (e.g. liquid), 500 mg
    J1569Injection, immune globulin (Gammagard), intravenous, non-lyophilized (e.g. liquid), 500 mg
    1–10 of 16
    1/2
    Common Procedure CodesCPT
    96365Common procedure code
    96366Common procedure code
    96367Common procedure code
    96368Common procedure code
    96374Common procedure code
    96375Common procedure code
    90284Common procedure code

    Provider Requirements

    Prior Authorization

    Prior Authorization Required

    The following immune globulin products require prior authorization under the medical benefit.

    • J1459 — Privigen, intravenous immune globulin, 500 mg
    • J1552 — Alyglo, 500 mg
    • J1554 — Asceniv, 500 mg
    • J1556 — Bivigam, 500 mg
    • J1555 — Cuvitru
    • J1557 — Gammaplex, intravenous immune globulin, 500 mg
    • J1561 — Gamunex-C/Gammaked, intravenous immune globulin, 500 mg
    • J1566 — Intravenous immune globulin, lyophilized, not otherwise specified, 500 mg; only Carimune NF and Gammagard S/D should be billed using this code
    • J1568 — Octagam, intravenous immune globulin, 500 mg
    • J1569 — Gammagard, intravenous immune globulin, 500 mg
    • J1572 — Flebogamma/Flebogamma DIF, intravenous immune globulin, 500 mg
    • J1559 — Hizentra, subcutaneous immune globulin, 100 mg
    • J1575 — HyQvia, subcutaneous immune globulin, 100 mg

    Therapy Background

    Intravenous immunoglobulin provides antibodies for people who are susceptible to diseases for which there are no immunizations or who are immune deficient. Subcutaneous human immune globulin supplies a broad spectrum of opsonizing and neutralizing IgG antibodies and is used to treat primary immune deficiency.

    Therapy Definitions

    Intravenous Immunoglobulin Therapy (IVIG)
    TherapyIntravenous immunoglobulin therapy (IVIG)
    AdministrationAdministered intravenously to provide antibodies.
    Clinical purposeUsed for people who are susceptible to diseases for which there are no immunizations or who are immune deficient.
    Immune Globulin Subcutaneous (Human) (SCIG)
    TherapyImmune Globulin Subcutaneous (Human) (SCIG)
    AdministrationAdministered subcutaneously.
    Clinical purpose

    Initial Therapy

    Initial Immunoglobulin Therapy

    Initial coverage is subject to Medicare Part B guidance and prior authorization.

    Initial coverage requirements: Use an applicable Medicare coverage determination or policy article for the requested therapy, obtain IVIG or SCIG from a preferred contracted IVIG vendor, and limit the initial coverage period to up to 3 months.up to 3 months

    IVIG for primary immunodeficiency is covered under Part B in all treatment settings; home administration is not required.

    Extension of Therapy

    Extension of Therapy

    Continuation requests require supporting clinical documentation.

    Continuation requirements: Submit all pertinent laboratory reports and objective evidence of improvement with the continuation request.

    Extensions are authorized for up to 6 months.

    Covered Treatment Settings

    Note

    Home IVIG is a covered setting

    IVIG is covered under the Part B benefit in the home setting for primary immunodeficiency. Medicare members are not required to receive IVIG in the home setting.

    • Use LCD L33610 and Policy Article A52509 for current IVIG coverage guidance.
    Note

    Office IVIG is a covered setting

    IVIG is covered under the Part B benefit in the office setting for primary immunodeficiency.

    • Use LCD L33610 and Policy Article A52509 for current IVIG coverage guidance.
    Note

    Infusion-center IVIG is a covered setting

    IVIG is covered under the Part B benefit in an infusion center for primary immunodeficiency.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Immunoglobulin Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain IVIG or SCIG from a preferred contracted IVIG vendor and secure prior authorization when billed under the medical benefit.
    SourceLink
    On This Page
    Coverage CriteriaBilling and Procedure CodesProvider RequirementsTherapy BackgroundTherapy DefinitionsInitial TherapyExtension of TherapyCovered Treatment Settings
  1. J1576 — Panzyga, intravenous immune globulin, 500 mg
  2. J1551 — Cutaquig, subcutaneous immune globulin, 100 mg
  3. J1558 — Xembify, subcutaneous immune globulin, 100 mg
  4. Billing Rule

    Preferred Contracted Vendor

    Obtain IVIG and SCIG products from the preferred contracted IVIG vendor.

    Documentation Required

    Continuation Documentation

    Submit continuation-of-therapy requests with complete clinical documentation demonstrating ongoing benefit.

    • Include all pertinent laboratory reports.
    • Include objective evidence of improvement.
    • Extensions of therapy may be approved for up to 6 months.
    Note

    Medicare Coverage Guidance

    Submit Medicare requests in accordance with the applicable current CMS coverage guidance, including relevant NCDs, LCDs, and accompanying policy articles.

    • For IVIG coverage, refer to LCD L33610 and Policy Article A52509.
    • For home-administered subcutaneous immune globulin, refer to LCD L33794 for External Infusion Pumps and Policy Article A52507.
    • IVIG is covered under the Medicare Part B benefit in all treatment settings for Primary Immunodeficiency; Medicare members are not required to receive IVIG in the home setting.
    • Check the Medicare Part D formulary for drugs that may be covered under the Part D benefit.
    Denial Risk

    Outside FDA Labeling Excluded

    Coverage is excluded when the patient age, dose, dosing frequency, or duration of therapy is outside FDA-approved package labeling.

    Denial Risk

    Condition Not Addressed by Policy

    Conditions not addressed by this policy require case-by-case review and must meet the criteria for Experimental and Investigational therapies for coverage under Medicare Part B.

    Used for the treatment of primary immune deficiency.
    Antibody coverageSupplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial agents.
    • Use LCD L33610 and Policy Article A52509 for current IVIG coverage guidance.
    Note

    Hospital outpatient IVIG is a covered setting

    IVIG is covered under the Part B benefit in the hospital outpatient setting for primary immunodeficiency.

    • Use LCD L33610 and Policy Article A52509 for current IVIG coverage guidance.
    Documentation Required

    Follow external infusion pump guidance for home SCIG

    Home SCIG coverage follows Medicare guidance under the external infusion pump policy. Refer to LCD L33794 and Policy Article A52507 for coverage guidance.

    • Confirm coverage under the applicable external infusion pump requirements.